Shopping Cart
Remove All
Your shopping cart is currently empty
Etaracizumab (LM 609) is a humanized monoclonal antibody targeting integrin αvβ3, inhibiting angiogenesis and melanoma growth, used in the study of melanoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 5 mg | $753 | In Stock | In Stock | |
| 10 mg | $1,180 | - | In Stock | |
| 25 mg | $1,780 | - | In Stock | |
| 50 mg | $2,380 | - | In Stock |
| Description | Etaracizumab (LM 609) is a humanized monoclonal antibody targeting integrin αvβ3, inhibiting angiogenesis and melanoma growth, used in the study of melanoma. |
| In vivo | In the SKOV3ip1 model, both Bevacizumab (5 mg/kg twice weekly) and Etaracizumab (10 mg/kg twice weekly) reduced tumor growth by 52-63%, compared with either drug alone. The combination treatment reduced growth by 63-74%. |
| Synonyms | MEDI523, MEDI 523, LM609, LM 609, Anti-αvβ3 Integrin Recombinant Antibody |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 144.3 (kDa) |
| Cas No. | 892553-42-3 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | IgG |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.